

Job Aid

Publication List

Index Lesion Theory

<https://pubmed.ncbi.nlm.nih.gov/24444476/>

van den Bos, W., Muller, B. G., Ahmed, H., Bangma, C. H., Barret, E., Crouzet, S., Eggener, S. E., Gill, I. S., Joniau, S., Kovacs, G., Pahernik, S., de la Rosette, J. J., Rouvière, O., Salomon, G., Ward, J. F., & Scardino, P. T. (2014). Focal therapy in prostate cancer: international multidisciplinary consensus on trial design. *European urology*, 65(6), 1078–1083. <https://doi.org/10.1016/j.eururo.2014.01.001>

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2839160/>

Liu, W., Laitinen, S., Khan, S., Vihinen, M., Kowalski, J., Yu, G., Chen, L., Ewing, C. M., Eisenberger, M. A., Carducci, M. A., Nelson, W. G., Yegnasubramanian, S., Luo, J., Wang, Y., Xu, J., Isaacs, W. B., Visakorpi, T., & Bova, G. S. (2009). Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. *Nature medicine*, 15(5), 559–565. <https://doi.org/10.1038/nm.1944>

[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(12\)70388-1/fulltext](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(12)70388-1/fulltext)

Ahmed, H. U., Arya, M., Freeman, A., & Emberton, M. (2012). Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy? *The Lancet. Oncology*, 13(11), e509–e517. [https://doi.org/10.1016/S1470-2045\(12\)70388-1](https://doi.org/10.1016/S1470-2045(12)70388-1)

Patient Selection

<https://pubmed.ncbi.nlm.nih.gov/28349978/>

Tay, K. J., Scheltema, M. J., Ahmed, H. U., Barret, E., Coleman, J. A., Dominguez-Escrig, J., Ghai, S., Huang, J., Jones, J. S., Klotz, L. H., Robertson, C. N., Sanchez-Salas, R., Scionti, S., Sivaraman, A., de la Rosette, J., & Polascik, T. J. (2017). Patient selection for prostate focal therapy in the era of active surveillance: an International Delphi Consensus Project. *Prostate cancer and prostatic diseases*, 20(3), 294–299. <https://doi.org/10.1038/pcan.2017.8>

<https://pubmed.ncbi.nlm.nih.gov/38613454/>

Rodríguez-Sánchez, L., Reiter, R., Rodríguez, A., Emberton, M., de Reijke, T., Compérat, E. M., Bossi, A., & Sanchez-Salas, R. (2024). The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer. *BJU international*, 134(1), 50–53. <https://doi.org/10.1111/bju.16360>

Patient Selection (Continued)

<https://pubmed.ncbi.nlm.nih.gov/31316185/>

Stabile, A., Giganti, F., Rosenkrantz, A. B., Taneja, S. S., Villeirs, G., Gill, I. S., Allen, C., Emberton, M., Moore, C. M., & Kasivisvanathan, V. (2020). Multiparametric MRI for prostate cancer diagnosis: current status and future directions. *Nature reviews. Urology*, 17(1), 41–61. <https://doi.org/10.1038/s41585-019-0212-4>

<https://pubmed.ncbi.nlm.nih.gov/28110982/>

Ahmed, H. U., El-Shater Bosaily, A., Brown, L. C., Gabe, R., Kaplan, R., Parmar, M. K., Collaco-Moraes, Y., Ward, K., Hindley, R. G., Freeman, A., Kirkham, A. P., Oldroyd, R., Parker, C., Emberton, M., & PROMIS study group (2017). Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. *Lancet* (London, England), 389(10071), 815–822. [https://doi.org/10.1016/S0140-6736\(16\)32401-1](https://doi.org/10.1016/S0140-6736(16)32401-1)

<https://pubmed.ncbi.nlm.nih.gov/25711199/>

Le Nobin, J., Rosenkrantz, A. B., Villers, A., Orczyk, C., Deng, F. M., Melamed, J., Mikheev, A., Rusinek, H., & Taneja, S. S. (2015). Image Guided Focal Therapy for Magnetic Resonance Imaging Visible Prostate Cancer: Defining a 3-Dimensional Treatment Margin Based on Magnetic Resonance Imaging Histology Co-Registration Analysis. *The Journal of urology*, 194(2), 364–370. <https://doi.org/10.1016/j.juro.2015.02.080>

<https://pubmed.ncbi.nlm.nih.gov/35115177/>

Brisbane, W. G., Priester, A. M., Ballon, J., Kwan, L., Delfin, M. K., Felker, E. R., Sisk, A. E., Hu, J. C., & Marks, L. S. (2022). Targeted Prostate Biopsy: Umbra, Penumbra, and Value of Perilesional Sampling. *European urology*, 82(3), 303–310. <https://doi.org/10.1016/j.eururo.2022.01.008>

<https://pubmed.ncbi.nlm.nih.gov/28830754/>

Nassiri, N., Chang, E., Lieu, P., Priester, A. M., Margolis, D. J. A., Huang, J., Reiter, R. E., Dorey, F. J., Marks, L. S., & Natarajan, S. (2018). Focal Therapy Eligibility Determined by Magnetic Resonance Imaging/Ultrasound Fusion Biopsy. *The Journal of urology*, 199(2), 453–458. <https://doi.org/10.1016/j.juro.2017.08.085>

<https://pubmed.ncbi.nlm.nih.gov/33069628/>

Fasulo, V., Cowan, J. E., Maggi, M., Washington, S. L., 3rd, Nguyen, H. G., Shinohara, K., Lazzeri, M., Casale, P., & Carroll, P. R. (2022). Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. *European urology oncology*, 5(1), 61–69. <https://doi.org/10.1016/j.euo.2020.08.002>

<https://pubmed.ncbi.nlm.nih.gov/34285350/>

Vince, R. A., Jr, Jiang, R., Qi, J., Tosoian, J. J., Takele, R., Feng, F. Y., Linsell, S., Johnson, A., Shetty, S., Hurley, P., Miller, D. C., George, A., Ghani, K., Sun, F., Seymore, M., Dess, R. T., Jackson, W. C., Schipper, M., Spratt, D. E., & Morgan, T. M. (2022). Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative. *Prostate cancer and prostatic diseases*, 25(4), 677–683. <https://doi.org/10.1038/s41391-021-00428-y>

Energy Modalities and Outcomes

<https://pubmed.ncbi.nlm.nih.gov/29960750/>

Guillaumier, S., Peters, M., Arya, M., Afzal, N., Charman, S., Dudderidge, T., Hosking-Jervis, F., Hindley, R. G., Lewi, H., McCartan, N., Moore, C. M., Nigam, R., Ogden, C., Persad, R., Shah, K., van der Meulen, J., Virdi, J., Winkler, M., Emberton, M., & Ahmed, H. U. (2018). A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer. *European urology*, 74(4), 422–429. <https://doi.org/10.1016/j.eururo.2018.06.006>

<https://pubmed.ncbi.nlm.nih.gov/35123819/>

Reddy, D., Peters, M., Shah, T. T., van Son, M., Tanaka, M. B., Huber, P. M., Lomas, D., Rakauskas, A., Miah, S., Eldred-Evans, D., Guillaumier, S., Hosking-Jervis, F., Engle, R., Dudderidge, T., Hindley, R. G., Emara, A., Nigam, R., McCartan, N., Valerio, M., Afzal, N., ... Ahmed, H. U. (2022). Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. *European urology*, 81(4), 407–413. <https://doi.org/10.1016/j.eururo.2022.01.005>

<https://pubmed.ncbi.nlm.nih.gov/35714666/>

Ehdaie, B., Tempany, C. M., Holland, F., Sjoberg, D. D., Kibel, A. S., Trinh, Q. D., Durack, J. C., Akin, O., Vickers, A. J., Scardino, P. T., Sperling, D., Wong, J. Y. C., Yuh, B., Woodrum, D. A., Mynderse, L. A., Raman, S. S., Pantuck, A. J., Schiffman, M. H., McClure, T. D., Sonn, G. A., ... Ghanouni, P. (2022). MRI-guided focused ultrasound focal therapy for patients with intermediate-risk prostate cancer: a phase 2b, multicentre study. *The Lancet. Oncology*, 23(7), 910–918. [https://doi.org/10.1016/S1470-2045\(22\)00251-0](https://doi.org/10.1016/S1470-2045(22)00251-0)

<https://pubmed.ncbi.nlm.nih.gov/30638633/>

Shah, T. T., Peters, M., Eldred-Evans, D., Miah, S., Yap, T., Faure-Walker, N. A., Hosking-Jervis, F., Thomas, B., Dudderidge, T., Hindley, R. G., McCracken, S., Greene, D., Nigam, R., Valerio, M., Minhas, S., Winkler, M., Arya, M., & Ahmed, H. U. (2019). Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. *European urology*, 76(1), 98–105. <https://doi.org/10.1016/j.eururo.2018.12.030>

<https://pubmed.ncbi.nlm.nih.gov/36775929/>

Aker, M. N., Brisbane, W. G., Kwan, L., Gonzalez, S., Priester, A. M., Kinnaird, A., Delfin, M. K., Felker, E., Sisk, A. E., Kuppermann, D., & Marks, L. S. (2023). Cryotherapy for partial gland ablation of prostate cancer: Oncologic and safety outcomes. *Cancer medicine*, 12(8), 9351–9362. <https://doi.org/10.1002/cam4.5692>

<https://pubmed.ncbi.nlm.nih.gov/36495481/>

Scheltema, M. J., Geboers, B., Blazeovski, A., Doan, P., Katelaris, A., Agrawal, S., Barreto, D., Shnier, R., Delprado, W., Thompson, J. E., & Stricker, P. D. (2023). Median 5-year outcomes of primary focal irreversible electroporation for localised prostate cancer. *BJU international*, 131 Suppl 4, 6–13. <https://doi.org/10.1111/bju.15946>

Energy Modalities and Outcomes (Continued)

<https://pubmed.ncbi.nlm.nih.gov/39196716/>

Fainberg, J., Lee, T., Vertosick, E. A., Sivaraman, A., Chesnut, G., Fine, S. W., Eastham, J., Coleman, J., & Ehdaie, B. (2024). Targeted Ablation Using Ultrasound-Guided Irreversible Electroporation of Index Tumors (TARGET Study): Prospective Development Study Evaluating Safety, Patient-Reported Outcomes, and Oncologic Efficacy. *Urology practice*, 101097UPJ00000000000000666. Advance online publication. <https://doi.org/10.1097/UPJ.00000000000000666>

<https://pubmed.ncbi.nlm.nih.gov/27449263/>

Eggner, S. E., Yousuf, A., Watson, S., Wang, S., & Oto, A. (2016). Phase II Evaluation of Magnetic Resonance Imaging Guided Focal Laser Ablation of Prostate Cancer. *The Journal of urology*, 196(6), 1670–1675. <https://doi.org/10.1016/j.juro.2016.07.074>

Treatment, monitoring, and Follow-up

<https://pubmed.ncbi.nlm.nih.gov/35059352/>

Fainberg, J. S., Al Hussein Al Awamlh, B., DeRosa, A. P., Chesnut, G. T., Coleman, J. A., Lee, T., & Ehdaie, B. (2021). A systematic review of outcomes after thermal and nonthermal partial prostate ablation. *Prostate international*, 9(4), 169–175. <https://doi.org/10.1016/j.pnil.2021.04.001>

<https://pubmed.ncbi.nlm.nih.gov/32444261/>

Stabile, A., Orczyk, C., Giganti, F., Moschini, M., Allen, C., Punwani, S., Cathala, N., Ahmed, H. U., Cathelineau, X., Montorsi, F., Emberton, M., Briganti, A., Sanchez-Salas, R., & Moore, C. M. (2020). The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. *European urology*, 78(2), 155–160. <https://doi.org/10.1016/j.eururo.2020.04.068>

<https://pubmed.ncbi.nlm.nih.gov/30069583/>

Hötter, A. M., Meier, A., Mazaheri, Y., Zheng, J., Capanu, M., Chaim, J., Sosa, R., Coleman, J., Hricak, H., & Akin, O. (2019). Temporal changes in MRI appearance of the prostate after focal ablation. *Abdominal radiology (New York)*, 44(1), 272–278. <https://doi.org/10.1007/s00261-018-1715-9>

<https://pubmed.ncbi.nlm.nih.gov/29948045/>

Tay, K. J., Amin, M. B., Ghai, S., Jimenez, R. E., Kench, J. G., Klotz, L., Montironi, R., Muto, S., Rastinehad, A. R., Turkbey, B., Villers, A., & Polascik, T. J. (2019). Surveillance after prostate focal therapy. *World journal of urology*, 37(3), 397–407. <https://doi.org/10.1007/s00345-018-2363-y>

www.angiodynamics.com

* AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics, Inc., an affiliate, or a subsidiary.

© 2025 AngioDynamics, Inc.